<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30098066</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>10</Month>            <Day>12</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>12</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1349-7006</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>109</Volume>                    <Issue>10</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                    </PubDate>                </JournalIssue>                <Title>Cancer science</Title>                <ISOAbbreviation>Cancer Sci.</ISOAbbreviation>            </Journal>            <ArticleTitle>Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.</ArticleTitle>            <Pagination>                <MedlinePgn>3183-3196</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1111/cas.13763</ELocationID>            <Abstract>                <AbstractText>Compensatory activation of the signal transduction pathways is one of the major obstacles for the targeted therapy of non-small cell lung cancer (NSCLC). Herein, we present the therapeutic strategy of combined targeted therapy against the MEK and phosphoinositide-3 kinase (PI3K) pathways for acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in NSCLC. We investigated the efficacy of combined trametinib plus taselisib therapy using experimentally established EGFR-TKI-resistant NSCLC cell lines. The results showed that the feedback loop between MEK/ERK and PI3K/AKT pathways had developed in several resistant cell lines, which caused the resistance to single-agent treatment with either inhibitor alone. Meanwhile, the combined therapy successfully regulated the compensatory activation of the key intracellular signals and synergistically inhibited the cell growth of those cells in vitro and in vivo. The resistance mechanisms for which the dual kinase inhibitor therapy proved effective included (MET) mesenchymal-epithelial transition factor amplification, induction of epithelial-to-mesenchymal transition (EMT) and EGFR T790M mutation. In further analysis, the combination therapy induced the phosphorylation of p38 MAPK signaling, leading to the activation of apoptosis cascade. Additionally, long-term treatment with the combination therapy induced the conversion from EMT to mesenchymal-to-epithelial transition in the resistant cell line harboring EMT features, restoring the sensitivity to EGFR-TKI. In conclusion, our results indicate that the combined therapy using MEK and PI3K inhibitors is a potent therapeutic strategy for NSCLC with the acquired resistance to EGFR-TKIs.</AbstractText>                <CopyrightInformation>© 2018 The Authors. Cancer Science published by John Wiley &amp; Sons Australia, Ltd on behalf of Japanese Cancer Association.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Sato</LastName>                    <ForeName>Hiroki</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Thoracic, Breast and Endocrine Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yamamoto</LastName>                    <ForeName>Hiromasa</ForeName>                    <Initials>H</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-5330-5460</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Thoracic, Breast and Endocrine Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sakaguchi</LastName>                    <ForeName>Masakiyo</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Cell Biology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Shien</LastName>                    <ForeName>Kazuhiko</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Thoracic, Breast and Endocrine Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tomida</LastName>                    <ForeName>Shuta</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Bioinformatics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Shien</LastName>                    <ForeName>Tadahiko</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Thoracic, Breast and Endocrine Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ikeda</LastName>                    <ForeName>Hirokuni</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Thoracic, Breast and Endocrine Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hatono</LastName>                    <ForeName>Minami</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Thoracic, Breast and Endocrine Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Torigoe</LastName>                    <ForeName>Hidejiro</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Thoracic, Breast and Endocrine Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Namba</LastName>                    <ForeName>Kei</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Thoracic, Breast and Endocrine Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yoshioka</LastName>                    <ForeName>Takahiro</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Clinical Genomic Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kurihara</LastName>                    <ForeName>Eisuke</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Thoracic, Breast and Endocrine Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ogoshi</LastName>                    <ForeName>Yusuke</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Thoracic, Breast and Endocrine Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Takahashi</LastName>                    <ForeName>Yuta</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Thoracic, Breast and Endocrine Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Soh</LastName>                    <ForeName>Junichi</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Thoracic, Breast and Endocrine Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Toyooka</LastName>                    <ForeName>Shinichi</ForeName>                    <Initials>S</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-7588-6745</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Thoracic, Breast and Endocrine Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Clinical Genomic Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>16H05431</GrantID>                    <Agency>Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>14</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Cancer Sci</MedlineTA>            <NlmUniqueID>101168776</NlmUniqueID>            <ISSNLinking>1347-9032</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="C582924">2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D010077">Oxazepines</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D011728">Pyridones</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D011744">Pyrimidinones</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>33E86K87QN</RegistryNumber>                <NameOfSubstance UI="C560077">trametinib</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.1.-</RegistryNumber>                <NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.10.1</RegistryNumber>                <NameOfSubstance UI="C512478">EGFR protein, human</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.10.1</RegistryNumber>                <NameOfSubstance UI="D011958">Receptor, Epidermal Growth Factor</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.12.2</RegistryNumber>                <NameOfSubstance UI="D020929">Mitogen-Activated Protein Kinase Kinases</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Cell. 2010 Jan 19;17(1):77-88</RefSource>                <PMID Version="1">20129249</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50</RefSource>                <PMID Version="1">16199517</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Biol Chem. 2000 Nov 24;275(47):36803-10</RefSource>                <PMID Version="1">10969078</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Sci Rep. 2017 Jan 13;7:40847</RefSource>                <PMID Version="1">28084458</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Discov. 2017 Jul;7(7):704-715</RefSource>                <PMID Version="1">28331003</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2013 May 15;73(10):3051-61</RefSource>                <PMID Version="1">23542356</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Sci. 2018 Oct;109(10):3183-3196</RefSource>                <PMID Version="1">30098066</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2017 Apr 11;8(15):24604-24620</RefSource>                <PMID Version="1">28445948</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Pharm Biomed Anal. 2016 Jul 15;126:117-23</RefSource>                <PMID Version="1">27187764</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Invest. 2011 Nov;121(11):4311-21</RefSource>                <PMID Version="1">21985784</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Clin Oncol. 2015 Aug;12(8):445-64</RefSource>                <PMID Version="1">25850553</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2018 Jan 11;378(2):113-125</RefSource>                <PMID Version="1">29151359</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Front Med. 2016 Dec;10(4):383-388</RefSource>                <PMID Version="1">27770386</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2012 Jul 1;72(13):3228-37</RefSource>                <PMID Version="1">22552284</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Cell. 2012 Feb 14;21(2):227-39</RefSource>                <PMID Version="1">22340595</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Discov. 2012 Oct;2(10):934-47</RefSource>                <PMID Version="1">22961667</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Sci. 2011 Nov;102(11):2038-42</RefSource>                <PMID Version="1">21801281</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Dermatol. 2018 Apr;45(4):397-407</RefSource>                <PMID Version="1">29399853</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Genet. 2003 Jul;34(3):267-73</RefSource>                <PMID Version="1">12808457</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96</RefSource>                <PMID Version="1">24556840</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2005 Feb 24;352(8):786-92</RefSource>                <PMID Version="1">15728811</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Trends Biochem Sci. 2007 Aug;32(8):364-71</RefSource>                <PMID Version="1">17624785</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biochem Soc Trans. 2012 Feb;40(1):79-84</RefSource>                <PMID Version="1">22260669</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Med. 2008 Dec;14(12):1351-6</RefSource>                <PMID Version="1">19029981</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cell. 2013 Apr 11;50(1):43-55</RefSource>                <PMID Version="1">23453810</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Science. 2004 Jun 4;304(5676):1497-500</RefSource>                <PMID Version="1">15118125</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Thorac Oncol. 2016 Jan;11(1):e1-4</RefSource>                <PMID Version="1">26762749</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2004 May 20;350(21):2129-39</RefSource>                <PMID Version="1">15118073</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Cancer. 2009 Oct 1;125(7):1575-86</RefSource>                <PMID Version="1">19462441</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2015 Dec 15;21(24):5499-5510</RefSource>                <PMID Version="1">26272063</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biochem J. 2010 Aug 1;429(3):403-17</RefSource>                <PMID Version="1">20626350</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Chemother Pharmacol. 2013 Jun;71(6):1395-409</RefSource>                <PMID Version="1">23443307</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>EMBO Rep. 2010 Sep;11(9):670-7</RefSource>                <PMID Version="1">20706219</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Sci. 2015 Oct;106(10):1377-84</RefSource>                <PMID Version="1">26202045</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2005 Aug 15;65(16):7096-101</RefSource>                <PMID Version="1">16103058</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Science. 2007 May 18;316(5827):1039-43</RefSource>                <PMID Version="1">17463250</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2014 Mar 1;20(5):1212-22</RefSource>                <PMID Version="1">24443523</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell Adh Migr. 2015;9(4):317-24</RefSource>                <PMID Version="1">26241004</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Sci Transl Med. 2011 Mar 23;3(75):75ra26</RefSource>                <PMID Version="1">21430269</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2017 Oct;18(10):1307-1316</RefSource>                <PMID Version="1">28919011</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2015 Oct 1;75(19):3997-4002</RefSource>                <PMID Version="1">26377941</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell. 2011 Nov 11;147(4):759-72</RefSource>                <PMID Version="1">22078877</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Adv Cancer Res. 2004;92:95-118</RefSource>                <PMID Version="1">15530558</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2007 Jun 15;13(12):3713-23</RefSource>                <PMID Version="1">17575237</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2008 Nov 15;68(22):9479-87</RefSource>                <PMID Version="1">19010923</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Sci Signal. 2013 Sep 24;6(294):re6</RefSource>                <PMID Version="1">24065147</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Med. 2015 Jun;21(6):560-2</RefSource>                <PMID Version="1">25939061</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D058750" MajorTopicYN="N">Epithelial-Mesenchymal Transition</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D020929" MajorTopicYN="N">Mitogen-Activated Protein Kinase Kinases</DescriptorName>                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D010077" MajorTopicYN="N">Oxazepines</DescriptorName>                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011728" MajorTopicYN="N">Pyridones</DescriptorName>                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011744" MajorTopicYN="N">Pyrimidinones</DescriptorName>                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011958" MajorTopicYN="N">Receptor, Epidermal Growth Factor</DescriptorName>                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">MEK inhibitor</Keyword>            <Keyword MajorTopicYN="N">PI3K inhibitor</Keyword>            <Keyword MajorTopicYN="N">acquired resistance</Keyword>            <Keyword MajorTopicYN="N">compensatory activation</Keyword>            <Keyword MajorTopicYN="N">non-small cell lung cancer</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>04</Month>                <Day>09</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>07</Month>                <Day>18</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>29</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30098066</ArticleId>            <ArticleId IdType="doi">10.1111/cas.13763</ArticleId>            <ArticleId IdType="pmc">PMC6172047</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>